Inhibition of glycogen synthase kinase 3β (GSK3β) is a shared action believed to be involved in the regulation of behavior by psychoactive drugs such as antipsychotics and mood stabilizers. However, little is known about the identity of the substrates through which GSK3β affects behavior. We identified fragile X mental retardation-related protein 1 (FXR1P), a RNA binding protein associated to genetic risk for schizophrenia, as a substrate for GSK3β. Phosphorylation of FXR1P by GSK3β is facilitated by prior phosphorylation by ERK2 and leads to its down-regulation. In contrast, behaviorally effective chronic mood stabilizer treatments in mice inhibit GSK3β and increase FXR1P levels. In line with this, overexpression of FXR1P in the mouse prefrontal cortex also leads to comparable mood-related responses. Furthermore, functional genetic polymorphisms affecting either FXR1P or GSK3β gene expression interact to regulate emotional brain responsiveness and stability in humans. These observations uncovered a GSK3β/FXR1P signaling pathway that contributes to regulating mood and emotion processing. Regulation of FXR1P by GSK3β also provides a mechanistic framework that may explain how inhibition of GSK3β can contribute to the regulation of mood by psychoactive drugs in mental illnesses such as bipolar disorder. Moreover, this pathway could potentially be implicated in other biological functions, such as inflammation and cell proliferation, in which FXR1P and GSK3 are known to play a role. 
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glycogen synthase kinase 3 | mood | emotion processing | FXR1P | bipolar disorder G lycogen synthase kinase 3α and β (GSK3α/β) are two serine threonine kinases involved in myriads of biological functions ranging from metabolism to immunity and behavior (1, 2) . In particular, several single nucleotide polymorphisms (SNPs) in the GSK3B locus or in genes involved in GSK3β signaling have been identified as genetic risk factors for bipolar disorder and schizophrenia (3, 4) . In addition, GSK3β is inhibited-either directly or following its phosphorylation on Ser9 by AKT-in response to three major classes of psychiatric drugs that are mood stabilizers, antidepressants, and antipsychotics (5) (6) (7) (8) (9) (10) . Furthermore, pharmacological or genetic inhibition of GSK3β replicates behavioral effects of these drugs in rodents (11) .
Because of its potential implication in mental disorders and their treatment, pharmacological inhibition of GSK3β has become an attractive therapeutic strategy for mental illnesses (12) . However, several limitations associated to the selectivity and long-term toxicity of GSK3β inhibitors have remained serious obstacles (13, 14) . One interesting alternative would be to target GSK3β substrates that are involved in the regulation of behavior by this kinase. However, the nature of these substrates has remained elusive, and evidence for their role in regulating behavior in humans is scarce.
An important layer of complexity for the identification of substrates involved in the regulation of behavior by GSK3β comes from the fact that GSK3β displays a 500-1,000-fold preference toward phosphoproteins (2, 15, 16) . Indeed, most GSK3β substrates require prior phosphorylation to be phosphorylated by this kinase. This phenomenon, called "priming," results from the nature of the consensus amino acid sequence S/T 1 XXXpS/T 2 that is recognized and phosphorylated by GSK3β. In this sequence, the amino-terminal S/T 1 corresponds to the serine or threonine that is phosphorylated by GSK3β, X is any amino acid, and pS/T 2 is the serine or threonine that acts as a priming site for GSK3β. Because of this need for priming, phosphorylation by GSK3β may therefore be highly context dependent and vary with changes of cell signaling landscapes that could be permissive or nonpermissive for the priming of a specific substrate.
Among the psychoactive drugs that affect GSK3β activity, mood stabilizers are a heterogeneous class of pharmacological agents used for the management of bipolar disorder as well as adjunct therapy for depression and schizophrenia. Lithium is the prototypical member of this class of psychiatric drugs that also includes the antiepileptic drugs lamotrigine and sodium valproate. Chronic administration of lithium, valproate, or lamotrigine has been shown to increase the inhibitory phosphorylation of GSK3β as a result of AKT activation (8, (17) (18) (19) (20) .
Regulation of GSK3β in response to mood stabilizers has several behavioral readouts that are not presently explained by the action of this kinase on any of its known substrates. Inhibition of
Significance
This study provides a cellular mechanism for the regulation of behavioral dimensions pertinent to mood disorders. Inhibition of glycogen synthase kinase 3β (GSK3β) is a shared action of drugs used for bipolar disorder. However, the substrates through which this kinase regulates mood are not known. We identified fragile X mental retardation-related protein 1 (FXR1P) as a substrate for GSK3β. Phosphorylation of FXR1P by GSK3β would lead to its down-regulation. Overexpression of FXR1P in the mouse prelimbic cortex elicits behavioral responses comparable to those of drugs inhibiting GSK3β. Furthermore, functional gene polymorphisms affecting FXR1P or GSK3β gene expression interact to regulate emotional brain responsiveness and stability in humans. These observations indicate that regulation of FXR1P by GSK3β contributes to regulating mood and emotion processing.
exploratory locomotion is a known behavioral effect of GSK3β inhibition that is used to model "antimanic" effects (21, 22) . Furthermore, lithium treatments and inhibition of GSK3β have been shown to exert an effect similar to antidepressants by reducing immobility in the tail suspension test (TST) (8, (23) (24) (25) . Finally, lithium exerts GSK3β signaling-dependent effects similar to antidepressants and anxiolytics in the dark-light emergence test (DLET) (8, 24, 25) . In this test, mice are placed in a darkened compartment and allowed free exploration of darkened and adjoining lighted compartments. Reduced latency to explore the light compartment as well as an increase in time and activity in this compartment are general indices of drug effect on mood-related behavior (26) .
We identified two chronic treatments with sodium valproate (low-dose VAL 10 and high-dose VAL 25), which exhibit different behavioral effects in mice while resulting in comparable GSK3β inhibition. We have used this experimental paradigm to identify a substrate of GSK3β involved in the regulation of mood and emotions. This substrate, the fragile X mental retardationrelated protein 1 (FXR1P), belongs to a small family of RNA binding proteins that also includes the fragile X mental retardation protein (FMRP) (27) . Interestingly, SNPs in the FXR1 gene have recently been identify as genetic risk factors for schizophrenia (28) .
Our results indicate that FXR1P is down-regulated by GSK3β. Furthermore FXR1P is involved in the regulation of moodrelated behaviors in mice, whereas genetic, brain imaging, and behavioral evidence obtained from healthy human subjects revealed a role of GSK3B/FXR1 gene interactions in regulating emotional control. Taken together, these findings support a role of a GSK3β/FXR1P signaling pathway in regulating behavioral dimensions relevant to mood disorders in humans. Furthermore identification of a functional regulation of FXR1P by GSK3β suggests that this pathway may also be important for other biological processes such as inflammation in which involvement of these two proteins has been shown (29, 30) .
Results
Different Behavioral Outcomes from VAL 10 and VAL 25 Treatments with a Comparable Inhibitory Effect on GSK3β. To investigate potential dose-dependent effects of sodium valproate on GSK3β activity and behavior, mice were treated for 21 d with two different doses of sodium valproate: VAL 10 (10 g of sodium valproate per 1 kg of chow) or VAL 25 (25 g of sodium valproate per 1 kg of chow). Impact of treatment regimens on GSK3β (Ser-9) phosphorylation/inactivation was evaluated in the frontal cortex and striatum of mice treated with VAL 10 or VAL 25 or vehicle (normal chow). These two brain areas were chosen on the base of their known association with specific effects of GSK3β on locomotion in the case of the striatum and on mood/emotionrelated responses in the case of the frontal cortex (24, 31) . Both the VAL 10 and VAL 25 treatments resulted in an increased phosphorylation/inactivation of GSK3β compared with vehicle (Fig. 1A) . Quantification of GSK3β and its negative regulator AKT using near infrared immunoblot analysis showed that the effect of both valproate treatment regimens on the phosphorylation of these proteins was comparable in the striatum and frontal cortex ( Fig. 1 B and C) . Previous study has shown that mice lacking βARR2 do not display changes in GSK3β activity following chronic lithium treatment (8) . This suggests that these mice may provide a useful negative control model for the investigation of GSK3β regulation by mood stabilizers. Indeed, both valproate treatment Behavior was scored as latency to first cross to the illuminated (light) compartment, time spent in the light compartment, activity in the illuminated (light) compartment, and total distance traveled in both compartments for the whole duration of the 5-min test. Data are means ± SEM. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.005. For behavioral studies, one-way ANOVA with Bonferroni-corrected pair-wise comparisons was performed; n = 10 mice per group. For phosphorylation analysis, respective total protein signal was used as internal reference for phosphoproteins. Data were normalized to average protein levels in vehicle-treated animals. *P ≤ 0.05. Student double-tailed t test was performed (drug vs. vehicle within each genotype). n = 5 mice per group. Detection and quantification of immunoblot signal were performed within a linear signal range using near-infrared fluorescence and a LiCor Odyssey.
regimens failed to affect AKT and GSK3β phosphorylation in βARR2-KO mice (Fig. S1 ).
Mice were submitted to a series of behavioral tests that are responsive to lithium and selective GSK3β inhibition (8, 24) . When tested, mice receiving either of the valproate treatment regimens displayed a reduction of exploratory behavior (Fig. 1D ) that is similar to what is reported in mice treated with lithium or selective GSK3 inhibitors. In contrast, only mice treated under the VAL 10 conditions displayed a behavioral response in the TST (Fig. 1E ). This lack of response to the VAL 25 treatment was also observed in the DLET (Fig. 1F) . However, both treatment regimens reduced locomotion equally in this test, thus supporting that the lack of effects of the VAL 25 treatment on emotional dimensions of behavior in the DLET is not related to a greater reduction of locomotor activity.
Taken together, these observations indicate that, like it was reported for lithium (8) , chronic valproate treatments can exert several behavioral effects by inhibiting GSK3β. However, these effects are different between the VAL 10 and VAL 25 conditions, suggesting that high doses of valproate may recruit additional mechanisms that could interfere with the behavioral outcomes of GSK3β inhibition.
Behavioral Effects of VAL 10 Treatment Correlate with Increased FXR1P Levels. A combination of VAL 10 and VAL 25 treatment regimens in WT and βARR2-KO mice was used as a model system to examine whether putative GSK3β substrates are affected differentially by treatments having different behavioral effects. In addition to valproate treatments, two pharmacological agents-lithium and lamotrigine-that are known to increase brain GSK3β phosphorylation (8, 19) and exert behavioral responses in the TST and DLET ( Fig. S2 A and B) were also included as positive controls.
To identify possible new substrates involved in the regulation of behavior by GSK3β, we perused a list of putative primingdependent GSK3β substrates established as part of a proteomic screen aimed at identifying proteins that can be targeted for degradation following phosphorylation by GSK3β (32) . To maximize the chances of identifying a substrate with relevance to mental illnesses, this list was examined in light of existing literature on genetic loci associated to mental illness (28) . Among the possible candidates, FXR1P, a RNA binding protein related to FMRP (27) , was retained for further investigation.
The VAL 10 treatment as well as chronic treatment with lithium (15 d at a concentration of 0.12% wt/vol) or lamotrigine (21 d, 10 mg/kg, i.p.) all resulted in a robust up-regulation of FXR1P levels in the striatum and frontal cortex of mice ( Fig. 2A and Fig. S2 C-E). Nevertheless, this up-regulation of FXR1P was absent in mice treated with the VAL 25 regimen or in βARR2-KO mice treated either with lithium, lamotrigine, or valproate ( Fig. 2 A and B Fig. S2 D-F) . Because antibodies directed against fragile X family proteins are known to display some levels of cross-reactivity, results obtained with the commercial antibody were further confirmed using an additional anti-FXR1P ML-12 antibody (33) . Staining of the membranes with this antibody in Western blot (Fig. S2C ) confirmed the selective increase of FXR1P levels in response to the VAL 10 treatment. Notably, in addition to the full-length 70-kDa isoforms of FXR1P, this antibody also detected an up-regulation of a 50-kDa band that may correspond to a degradation product of this protein (30) .
Conditional GSK3β flox mice, lacking GSK3β expression in forebrain neurons as a result of a CamKII-driven Cre expression (24) , were used to establish the potential contribution of an inhibition of GSK3β to this effect. As illustrated (Fig. 2C ), neuronal GSK3β deficiency was accompanied by an increase in FXR1P levels in the frontal cortex of these mice compared with their Cre-negative littermates.
High-Dose Chronic Valproate Treatment Elicits Inhibition of ERK2.
Because behavioral differences observed between the VAL 10 and VAL 25 treatment cannot be explained by a lack of GSK3β inhibition, we have explored the effects of sodium valproate on different major signaling pathways that may affect its regulation by GSK3β.
We used acute administrations to identify signaling pathways that may be affected by a high dose (400 mg/kg i.p.) of sodium valproate. Examination of striatal protein phosphorylation by Western blot at different times postinjection revealed (Fig. 3A) that this treatment caused a reduction of ERK2 phosphorylation 2 h after drug injection without affecting the phosphorylation of DARPP-32, CREB, or JNK. Further characterization of this effect using protein extracts obtained from the striatum or frontal cortex of mice treated with different doses (200, 300, or 400 mg/kg i.p.) of sodium valproate (Fig. 3A) showed that reduced ERK2 phosphorylation/activity occurred in both structures but was only significant at a 400 mg/kg dose, suggesting that this effect could be associated with the detrimental impact of high-dose valproate on behavioral responses.
To further examine this possibility, ERK2 phosphorylation was assessed in mice following VAL 10 and VAL 25 treatments (Fig.  3B) . Although VAL 10 did not affect ERK2 phosphorylation, the VAL 25 treatment resulted in a reduction of ERK2 phosphorylation in both the cortex and striatum. Furthermore, this effect of VAL 25 on ERK2 phosphorylation did not occur in βARR2-KO mice (Fig. 3C) . Because βARR2 has been implicated in the regulation of ERK2 activity by several G protein coupled receptors (GPCR) (34) , this suggests that disruption of βARR2-mediated signaling by Black bars in A-C correspond to control vehicle conditions. For all analyses, respective total protein signal was used as the internal reference for phosphoproteins. Data (means ± SEM) were normalized to average protein levels in vehicle-treated animals from the same genotype. *P ≤ 0.05. Student double-tailed t test was performed (drug vs. vehicle within each genotype). n = 5 mice per group. Detection and quantification of immunoblot signal were performed within a linear signal range using near-infrared fluorescence and a LiCor Odyssey.
valproate in vivo is not restricted to mechanisms involving AKT and GSK3β. Interestingly, valproate has recently been shown to inhibit βARR2-mediated ERK2 activation downstream of the melatonin receptor type 1 in transfected HEK293 and Neuro2A cells (35) , therefore supporting our findings in vivo.
To evaluate if a cross-talk between GSK3β and ERK2 can affect the regulation of behavior by GSK3β, we then tested how coadministration of the ERK2 kinase MEK inhibitor SL327 (50 mg/kg i.p.) affects behavioral responses to lithium (LiCl 75 mg/kg) or to the selective GSK3 inhibitor TDZD-8 (30 mg/kg i.p.). These doses of lithium and TDZD-8 were selected based on their known effects in mice (8) . The dose of SL327 was selected to induce a level of ERK2 inhibition similar to the one resulting from the VAL 25 treatment in the mouse frontal cortex (Fig. S3  A and B) . As it may be expected, both lithium and TDZD-8 induced an antidepressant-like response in the DLET when administered alone (Fig. S3C) . However, this effect was fully abolished by coadministration of SL327.
Because valproate is a known inhibitor of class 1 histone deacetylase (HDAC1) (36), mice were treated with the HDAC1 inhibitor MS275 (20 mg/kg i.p. daily for 21 d) (37) to establish the impact of HDAC1 inhibition on FXR1P levels as well as ERK2, AKT, and GSK3β phosphorylation. Interestingly, MS275 treatment in WT animals did not affect FXR1P levels (Fig. S4A) or the phosphorylation of AKT, GSK3β, and ERK2 (Fig. S4B) . However, this same treatment exerted an antidepressant-like effect in the TST in both WT and βARR2-KO mice (Fig. S4C ). This suggests that like lithium, valproate regulates the activity of AKT and GSK3β and ERK2 via a βARR2-dependent mechanism that is independent from its effect on HDAC1 in vivo.
Regulation of the FXR1P Levels by GSK3β and ERK. A stable HEK293 cell line expressing a His-Tag recombinant mouse FXR1P under the control of a CMV promoter was generated to study the effects of ERK2 and GSK3β activity on FXR1P levels directly. Treatment of cells with GSK3 inhibitors TDZD-8, lithium, SB216763, and alsterpaullone resulted in an increase of the levels of the recombinant FXR1P (Fig. 4A) . Furthermore, expression of a constitutively active AKT resulted in an increase in the inhibitory phosphorylation of GSK3β accompanied by increased levels of recombinant FXR1P (Fig. S5A) . Conversely, expression of a constitutively active S9A mutant of GSK3β led to reductions of the recombinant FXR1P (Fig. S5B ) that was prevented by TDZD-8 (Fig. S5C) . Finally, although inhibition of ERK2 phosphorylation/activation by SL327 had no effect on the levels of recombinant FXR1P (Fig. 4B) , cotreatment with SL327 abolished the effects of TDZD-8 on recombinant FXR1P level without preventing the increase of endogenous β-catenin resulting from GSK3β inhibition (Fig. 4C) . β-catenin is a constituent of the Wnt pathway that is degraded by the ubiquitin proteasome system following its phosphorylation (38) . Taken together experiments conducted using the recombinant cell line suggest that GSK3β negatively regulates the FXR1P, potentially by targeting it for degradation, as it does for β-catenin. However, in contrast to the action of GSK3β on β-catenin, the action of this kinase is dependent upon a tonic activation of ERK2, therefore suggesting priming of FXR1P by ERK2 as a potential mechanism.
ERK2 Activity Favors FXR1P Phosphorylation and Regulation by
GSK3β. Examination of the FXR1P sequence (Fig. 4D) revealed the existence of nine putative GSK3β consensus sites localized in the carboxyl-terminal portion of the protein between amino acids 400 and 570. Interestingly, most of these sites are situated in a region of FXR1P that shows less than 6% homology with other proteins of the fragile X mental retardation family (27) . In vitro phosphorylation assays were carried out to establish whether FXR1P is For all analyses, respective total protein signal was used as the internal reference for phosphoproteins. Data (means ± SEM) were normalized to average protein levels in vehicle-treated animals from the same genotype. *P ≤ 0.05. Student double-tailed t test was performed (drug vs. vehicle within each genotype). n = 5 mice per group. Detection and quantification of immunoblot signal were performed within a linear signal range using near-infrared fluorescence and a LiCor Odyssey.
phosphorylated by GSK3β and ERK2. In a first set of experiments, His-Tag recombinant mouse FXR1P was immunoprecipitated from the stable HEK293 cell line and used as a substrate for phosphorylation. As shown (Fig. 4E) , incubation of the protein with radioactive [γ 32 P]ATP and recombinant GSK3β or ERK2 resulted in its phosphorylation. Interestingly, overnight pretreatment of HEK293 cells with SL237 before recombinant mouse FXR1P immunoprecipitation resulted in a reduction in the level of FXR1P phosphorylation by recombinant GSK3β (Fig. 4F) , therefore supporting the hypothesis that phosphorylation by ERK2 can facilitate the phosphorylation of FXR1P by GSK3β.
Because the phosphorylation of FXR1P by ERK2 cannot be fully inhibited in mammalian cells, recombinant FXR1P was produced in Escherichia coli to address the role of ERK2 in regulating . Black bars correspond to control vehicle conditions. Respective total protein signal was used as the internal reference for phosphoproteins. Actin was used as a reference for the measurement of changes in the relative levels of a given protein. Data (means ± SEM) were normalized to average protein levels in vehicle-treated cells. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.005. Student double-tailed t test was performed (drug vs. vehicle within each genotype). n = 5 separate cell cultures. Detection and quantification of immunoblot signal were performed within a linear signal range using near-infrared fluorescence and a LiCor Odyssey. (D) Identification of putative GSK3β phosphorylation sites within the His-FXR1P sequence. Individual serine and threonine (in black) are numbered. KH and RGG domains are indicated. (E) In vitro phosphorylation of recombinant HEK293 cell produced his-tagged FXR1P with radioactive ATP by recombinant GSK3β or ERK2. (F) Quantitative assessment of in vitro phosphorylation by recombinant GSK3β of recombinant his-tagged FXR1P produced in HEK293 cells that were incubated overnight with media containing SL327 (10 μM) or vehicle. Kinase assays were performed in parallel. Each lane corresponds to kinase assays made from different immunoprecipitates. Absorbance of the Coomassie blue (C. blue)-stained FXR1P band of corresponding immunoprecipitates was used as a control for variation of FXR1P abundance between immunoprecipitates. Data are means ± SEM; n = 3; *P ≤ 0.05 (Student double-tailed t test). (G) Effect of the ERK inhibitor pyraz (1 μM) on the phosphorylation by recombinant ERK2 of recombinant his-tagged FXR1P produced in E. coli (Top) and of the GSK3 substrate inhibitor 2 (I2) by recombinant GSK3β (Bottom). (H) Effect of a prior phosphorylation by ERK2 on the phosphorylation of E. coli produced his-tagged FXR1P by GSK3β in the presence of [γ 32 P]ATP. Recombinant his-tagged FXR1P was incubated with recombinant ERK2 and nonradioactive ATP to produce an ERK2 primed form of FXR1P (FXR1P′). This reaction was then stopped by addition of pyraz. FXR1P and FXR1P′ were used for phosphorylation assays in the presence of radioactive ATP. Additional bands in lanes 4 and 5 of the Coomassie blue-stained gel correspond to the human GST-GSK3β recombinant protein that was used in the assay. Gel presented is representative of five independent experiments. (I) In vitro phosphorylation assays of individual serine-threonine to alanine mutants of his-tagged FXR1P' produced in E. coli. All mutants were primed with ERK2 before kinase assay. Gel presented is representative of five independent experiments. (J) Quantitative immunoblot analysis of HA-FXR1P and HA-FXR1P alanine mutants after 60 min of treatment with TDZD-8 in 293-HEK cells. **P ≤ 0.01, ***P ≤ 0.005. One-way ANOVA with Bonferroni-corrected pair-wise comparisons was performed; n = 5 separate cell cultures. the phosphorylation of FXR1P by GSK3β. Incubation of bacterially produced recombinant FXR1P with ERK2 resulted in its phosphorylation (Fig. 4G) . Importantly, this action of ERK2 was abolished by its selective inhibitor 3-Methyl-5-pyrazolone (pyraz). However, pyraz did not prevent the phosphorylation of the GSK3β substrate (39) protein phosphatase inhibitor 2 (I2) by GSK3β (Fig.  4G ). This allowed for performing a phosphorylation of FXR1P by ERK2 in the presence of nonradioactive ATP to generate a primed recombinant FXR1P (FXR1P′) that was then treated with pyraz to inactivate ERK2 activity. Incubation of FXR1P or FXR1P′ with γP 32 -labeled ATP in the absence of additional kinases did not result in the incorporation of radioactive phosphates in either recombinant proteins, therefore indicating that pyraz totally inhibited the activity of ERK2 used to generate FXR1P′ (Fig.  4H, lanes 1 and 2) . Incubation of FXR1P with recombinant GSK3β resulted in a very low level of FXR1P phosphorylation (Fig. 4H, lane 4) . In contrast prephosphorylation of FXR1P by ERK2 allowed for a much greater level of phosphorylation of FXR1P′ by GSK3β (Fig. 4H, lane 5) , thus confirming that, at least in vitro, ERK2 phosphorylation facilitates phosphorylation of FXR1P by GSK3β.
To try identifying the site responsible for the phosphorylation of FXR1P′ by GSK3β, individual putative serine or threonine phosphorylation sites were mutated to alanine, and the nine different his-tagged recombinant mutants of FXR1P were produced in E. coli. Kinase assays were carried out on primed versions of these proteins. Although all mutations somewhat reduced the phosphorylation of FXR1P′ by GSK3β, no individual mutation was sufficient to fully abolish phosphorylation (Fig. 4I) , suggesting that multiple functional GSK3β sites are present in the carboxylterminal domain of FXR1P.
HA-tagged WT and mutant versions of FXR1P were generated. In a "full" mutant, all putative GSK3β phosphorylatable residues were mutated to alanine. Two partial mutants where only putative sites 4-6 or 7-9 ( Fig. 4D) were mutated to alanines were also made. Vectors encoding WT-HA-FXR1P or the different mutants were transiently transfected to HEK293 cells, and the impact of inhibition of GSK3 by TDZD-8 on HA-FXR1P levels was quantified by near-infrared immunoblot analysis (Fig.  4J) . The abundance of the WT-HA-FXR1P was elevated following treatment with TDZD-8. Furthermore, levels of the mutant lacking the putative phosphorylation sites 7-9 were also increased. In contrast, both the full mutant FXR1P and the mutant lacking sites 4, 5, and 6 were resistant to TDZD-8 treatment. Interestingly, basal levels of the full and 4-6 mutants were also elevated under control conditions compared with WT-HA-FXR1P. Taken together, these observations suggest that phosphorylation of FXR1P on sites 4, 5, and/or 6 is one of the factors contributing to the regulation of FXR1P by GSK3β.
FXR1P Overexpression Replicates Behavioral Effects of Valproate and
GSK3β Inhibition. The potential contribution of FXR1P to the effects resulting from the VAL 10 treatment and GSK3β inhibition was evaluated using an adeno-associated viral (AAV) vector overexpressing a recombinant GFP-FXR1P. Previous results obtained from CamKII-Cre/GSK3β flox mice have shown that inactivation of forebrain GSK3β is sufficient to induce responses in the DLET, while having no effect in the TST (24) . To further validate this site of intervention, the GSK3β gene was inactivated (Fig. S6A) in the prefrontal cortex of GSK3β flox mice using an AAV vector expressing a GFP-Cre fusion protein (40) . Evaluation of these mice in the DLET 3 wk after infection confirmed that inactivation of GSK3β in this brain area is sufficient to induce behavioral responses in this test (Fig. S6B ).
An AAV vector driving the expression of GFP-FXR1P in neurons under the control of a synapsin promoter was then used to assess behavioral consequences of FXR1P overexpression in this brain area (Fig. 5A) . Evaluation of FXR1P levels 3 wk after infection showed a robust GFP-FXR1P expression in the prelimbic prefrontal cortex (Fig. 5B) compared with control mice infected with a AAV vector driving the expression of GFP under the control of the same synapsin promoter. Furthermore, histological examination confirmed the presence of recombinant GFP-FXR1P in the cell body and MAP2-positive dendrites of infected cortical neurons (Fig. 5C ), thus confirming that the subcellular distribution of GFP-FXR1P corresponds to that of endogenous FXR1P (41) . Finally, overexpression of GFP-FXR1P in prelymbic prefrontal cortex neurons replicated the behavioral effects of GSK3β deletion and VAL 10 treatment in the DLET (Fig. 5 D-F) , indicating that an increase in FXR1P level is sufficient to exert effects similar to those of GSK3β inhibition on mood/emotion-related behaviors.
FXR1 Gene Polymorphism rs496250 Is Associated with mRNA Expression in Postmortem Human Brain. To support the biological interaction between GSK3β and FXR1P for phenotypes of relevance for mood regulation in humans, we explored if SNPs within genes encoding GSK3β and FXR1P (GSK3B, 3q13.3 and FXR1, 3q28, respectively) have functional interaction in modulating human brain activity and behavior related to emotion processing. In particular, we focused on GSK3B rs12630592 (G/T), for which the G allele has been associated with higher GSK3β expression (3). Furthermore, we investigated SNPs located in the promoter region of FXR1 and characterized in the publicly available database of postmortem brains Braincloud (42) . We identified two SNPs within the FXR1 promoter region, rs1805562 (A/C) and rs496250 (A/G), occurring 1,052 bp and 3,148 bp upstream of the gene, respectively. Age, sex, pH, RNA integrity number, and postmortem interval were homogeneously distributed among genotype groups for both SNPs (P > 0.05).
An analysis of covariance (ANCOVA) with the rs1805562 genotype as predictor and age as well as the Age × Genotype interaction as covariates of no interest did not reveal an effect of this genotype on FXR1 mRNA expression [F (1,90) = 0.0006; P > 0.9]. In contrast, a similar analysis indicated a main effect of rs496250 on the same dependent variable. In particular, subjects carrying the A allele of this SNP had higher levels of FXR1P mRNA compared with subjects homozygous for the G allele [F (1,90) = 6.40; P = 0.013] (Fig. S7A) .
Thus, we used rs496250 and rs12630592 as proxies of FXR1 and GSK3B gene expression level to be used in further analyses addressing the interaction between GSK3B and FXR1 variation on phenotypes related to emotion processing in healthy humans.
Interaction Between GSK3B and FXR1 Predicts Amygdala Activity During Processing of Facial Expressions. We investigated if the interaction between genetic variation within GSK3B and FXR1 affecting gene expression has functional effects on imaging phenotypes linked to physiological aspects of emotion processing. With this aim, we tested in healthy humans if GSK3B rs12630592 and FXR1 rs496250 have a combined effect on amygdala response while subjects implicitly evaluated facial expressions during fMRI. ANOVAs and χ 2 tests indicated that GSK3B/FXR1 genotype groups did not differ in terms of age, IQ, socioeconomic status, handedness, and behavioral performance at the fMRI task (all P > 0.1), whereas sex was unequally distributed between groups (χ 2 = 5.54; P = 0.02). Statistical parametric mapping ANCOVA with sex as a covariate of no interest indicated a main effect of facial expression in the left amygdala (x = -26, y = 4, z = -18; K = 122; Z = 5.47; FWE-P < 0.001), whereas there was no effect of FXR1 or of GSK3B variation in this brain region during processing of facial expressions. However, there was an interaction between FXR1 rs496250 and GSK3B rs12630592 in left amygdala activity (x = -20, y = -2, z = -18; K = 30; Z = 3.20; FWE-P = 0.026) (Fig. 5 G and H) . Analysis of BOLD response extracted from this significant cluster revealed that amygdala activity was modulated by GSK3B rs12630592 only in the context of FXR1 rs496250 A carriers. In particular, FXR1 rs496250 A carrier/GSK3B GG individuals had lower amygdala activity compared with FXR1 rs496250 A carrier/GSK3B TT (P < 0.001) and FXR1 rs496250 A carrier/GSK3B GT (P < 0.001) subjects. Furthermore, the latter group had lower amygdala activity than FXR1 rs496250 A carrier/GSK3B TT (P = 0.017) individuals. No modulation of amygdala activity by GSK3B rs12630592 was present in the context of FXR1 rs496250 GG genotype.
Interaction Between GSK3B and FXR1 Predicts Scores of "Emotional Stability" Within the BFQ. To investigate if GSK3B rs12630592 and FXR1 rs496250 also interact in modulating behavioral correlates of emotion processing in healthy individuals, we used the Big Five Questionnaire (BQF), which measures five aspects of personality including emotional stability (43) . In particular, individuals with low scores on emotional stability often report emotional instability and negative emotions such as anxiety, depression, or anger. Thus, we used emotional stability as the dimension of interest for our analysis. Genotype groups were matched for age, sex, full-scale IQ, and parental socioeconomical status (all Ps > 0.1). Factorial ANOVA indicated no main effects of GSK3B rs12630592 [F (2,147) = 1.69, P > 0.1] and of FXR1 rs496250 [F (1,147) = 1.79, P > 0.1) on emotional stability. However, there was a genotype/genotype interaction on this measure [F (2,147) = 3.66, P = 0.028]. Post hoc analysis revealed that in the context of low (GSK3B rs12630592 TT) to medium (GSK3B rs12630592 GT) GSK3B expression, FXR1 A carrier displayed higher emotional stability (Fig. 5I) . However, FXR1 A carriers/GSK3B GG subjectsthat have higher GSK3B expression-had lower scores than FXR1 A carriers/GSK3B GT and FXR1 A carriers/GSK3B TT individuals (Fig. 5I) . No significant effect of GSK3B rs12630592 was present in the context of FXR1 rs496250 GG genotype. Furthermore, other dimensions of the BQF were not affected by FXR1/GSK3B interactions (Fig. S7B) . These data support that increased expression of the GSK3β substrate FXR1P has a positive action on emotional stability in humans. Genetic interaction between FXR1 and GSK3B also supports a negative role for GSK3β in the regulation of FXR1P that is compatible with our observations in mice and in vitro systems.
Discussion
Results presented here identify FXR1P as a substrate of GSK3β involved in the regulation of mood and emotional control. Our findings in animals indicate that inhibition of neuronal GSK3β either in GSK3β flox mice or following chronic treatment with valproate, lamotrigine, or lithium results in an increase of FXR1P levels that coincides with the mood-related effects of these drugs and of GSK3β inhibition. Overexpression of FXR1P in the mouse prefrontal cortex elicits relevant behavioral responses even in βARR2-KO mice, which are generally resistant to the behavioral effects of mood stabilizers. Consistently, results in humans indicate that the genetic interaction of functional variations in FXR1 and GSK3B is associated with activity of the amygdala, a brain area involved in emotion processing that is innervated and regulated by the prefrontal cortex (44, 45) . Furthermore, FXR1/GSK3B interaction affects emotional behavior in healthy subjects in whom higher FXR1 expression is associated to greater emotional stability, except in the context of higher GSK3B expression. Together, these results suggest that the interplay between FXR1P and GSK3β is crucial in determining patterns of physiological and behavioral responses relevant to the modulation of emotional responses implicated in mood.
Our results in recombinant systems suggest that phosphorylation of one or several putative GSK3β sites is involved in regulating FXR1P levels, possibly by enhancing its degradation. However, whether this is the only way this regulation occurs in vivo and the precise nature of its mechanism will need to be characterized further. Additionally, GSK3α activity is also regulated in response to lithium (46) and other mood stabilizers. Because the two isoforms of GSK3 share several substrates (2), it is possible that GSK3α may contribute to the regulation of FXR1P. Our results also indicate that valproate can interfere with at least two modalities of βARR2-mediated signaling, the negative regulation of AKT and the activation of ERK2. Interestingly, a similar effect of valproate has recently been reported in neuroblastoma cells (35) . However, this effect does not seem to be apparent at all doses, as only the VAL 25 regimen resulted in a βARR2-dependent reduction of ERK activity in vivo. It is thus possible that the mechanisms of this interference may vary across signaling complexes downstream of different cell surface receptors. Characterization of these mechanisms represents another attractive topic for future investigations streaming from our observations. FXR1P is an RNA binding protein that belongs to the same family as FXR2 and FMRP. Proteins from this family have been mostly studied in the context of the fragile X mental retardation syndrome and autism spectrum disorders. Observation of a contribution of FXR1P to the regulation of mood and emotions suggests that the role of this family of proteins could be extended to other types of mental illnesses. FXR1P contains two KH domains and a RGG box that are implicated in mediating its interactions with mRNAs as well as with other proteins (47) . Although FMRP and to a lesser extent FXR2 have been extensively studied, little is known about the functions of FXR1P in the brain. One major limitation for such studies is that FXR1P gene knockout mice die shortly after birth due to a deficit in muscle formation (48) .
A study of hippocampal neurons has shown an association of FXR1P with neuronal polyribosomes in dendritic clusters (41) . Furthermore, FXR1P has been recently identified as a negative regulator for the translation of the ionotopic-glutamate AMPA receptor subunit GluA2. As a consequence of this, FXR1P would act as an inhibitor of protein synthesis-dependent longterm potentiation (49) . In this context, it is possible that by increasing FXR1P, GSK3β inhibition can act as a buffer by limiting synaptic plasticity. Interestingly, this consequence of GSK3β inhibition would be compatible with its putative involvement in mood stabilization.
In addition, FXR1P is also a known translational regulator of the tumor necrosis factor alpha (TNFα), a key cytokine involved in tumorigenesis and inflammation. Binding of FXR1P to the 3′ untranslated region of the TNFα mRNA in macrophages has been shown to inhibit its translation (50) . However, cross-regulation of this same mRNA by FXR1P and Argonaute 2 results in the opposite effect (30) . Interestingly, several lines of evidence suggest a role for inflammation and TNFα in mental illnesses including bipolar disorder and schizophrenia (51) (52) (53) . Furthermore, evidence for an anti-inflammatory action of mood stabilizers and of more selective GSK3β inhibitors has been reported (29) . It is therefore possible that FXR1P may exert its action on mood by regulating TNFα mRNA translation.
A large-scale association study identified FXR1 as a genetic risk factor for schizophrenia (28) . However, beyond genomewide association studies, the involvement of FXR1P in schizophrenia or other psychiatric illness is essentially unexplored. Our findings in mice and humans are suggestive of a role for the GSK3β/FXR1P pathway in regulating emotion processing and stability, behavioral dimensions involved in both schizophrenia and bipolar disorder. Furthermore, up-regulation of FXR1P is a shared consequence of behaviorally effective treatment with three major mood stabilizers, thus suggesting that it may contribute to the therapeutic action of these drugs. However, this will have to be firmly established by further research. Furthermore, our observations using MS275 in the TST also indicate that inhibition of HDAC1 activity may also contribute to the clinical actions of valproate independently of GSK3 and βARR2. Schizophrenia and bipolar disorder share several genetic risk factors (54, 55) , and defective GSK3β signaling is a suspected contributing mechanism to both disorders. However, additional research will be needed to firmly support this role of the GSK3β/ FXR1P signaling pathway and contemplate its use as a potential therapeutic opportunity. That being said, results presented here uncovered an unappreciated interaction between FXR1P and GSK3β with an involvement in regulating behavioral dimensions pertinent for mental illnesses.
Methods
Detailed experimental procedures are available in SI Methods. A list of primers used to generate the different FXR1P mutants is also provided in Table S1 .
Experimental Animals. All experimental procedures were approved by the Université Laval Institutional Animal Care Committee according to guidelines from the Canadian Council on Animal Care. Sodium valproate (SigmaAldrich) was administered for a period of 21 d in chow at a concentration of 10 (VAL 10) or 25 (VAL 25) g per 1 kg of chow as described (56) .
Quantitative Immunoblots. Euthanasia and immunoblot analyses were performed as described (21) and imaged in the near infrared using a Odyssey Imager (Licor Biotechnology).
Measurement of Locomotor Activity. Locomotion was evaluated under illuminated conditions in an automated Omnitech Digiscan apparatus (AccuScan Instruments) as described (21) .
TST. Mice were tested for 6 min in a tail suspension apparatus (Med-Associates) as described (23, 57) .
DLET. The DLET was performed as described (26, 57) . Tests were conducted using an automated open field activity setup with light/dark insert (MedAssociates).
Human Subjects. All subjects included in the human study provided written informed consent to the study after the procedure was fully explained to them. The protocol was approved by the local Institutional Review Board. Detailed experimental groups and statistical methods are available in SI Methods.
